Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Coronary Artery Calcium (Serial Calcium Scans)
研究概览
简要总结
Current oral anti-coagulation for atrial fibrillation is most commonly performed with warfarin. Warfarin is a vitamin K antagonist that has been shown in non-randomized trials to increase vascular calcification. Increased vascular calcification has been tied to increased cardiovascular events (CVE). This study will randomize patients currently taking warfarin to either continue on warfarin or be switched to rivaroxaban. Rivaroxaban is an oral anti-coagulant that works by inhibiting Factor Xa, and has no interaction with vitamin K. This study is a randomized, open label study that will randomize 120 patients and have them undergo blood tests and a calcium scan at baseline, and again after 12 months. Patients will be seen quarterly for examinations, safety checks and supply of rivaroxaban, as well as follow up INR testing for warfarin.
详细描述
Rivaroxaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with warfarin. The rate of myocardial infarction was 9% lower in the rivaroxaban group than in the warfarin group in the Rocket AF study and similarly the myocardial infarction rate was 12% lower in the apixaban group in Aristotle, but the difference was not significant in either trial. The potential of long term benefit by avoiding VKA therapy may be much greater for a CV event reduction. The study proposed will evaluate markers of CAC progression and atherosclerosis development, which have long term outcome data supporting that slowing these processes will be associated with lower CV events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible patients with atrial fibrillation at enrollment or two or more episodes of atrial fibrillation or flutter, as documented by electrocardiography, at least 2 weeks apart in the 12 months before enrollment
- •On Warfarin for 6 months prior to enrollment at a stable dose.
- •Willingness to participate in the study and ability to sign informed consent
- •Minimum CAC score of 10
排除标准
- •Atrial fibrillation due to a reversible cause, moderate or severe mitral stenosis, or conditions other than atrial fibrillation that require anticoagulation (e.g., a prosthetic heart valve)
- •Prior apixaban, dabigatran, rivaroxaban use.
- •A need for aspirin at a dose of >165 mg a day or for both aspirin and clopidogrel,
- •Renal insufficiency (serum creatinine level of 12.5 mg per deciliter or calculated creatinine clearance of <50 ml per minute).
- •Serious bleeding event in the previous 6 months or a high risk of bleeding (eg, active peptic ulcer disease, a platelet count of <100,000/mm3 or hemoglobin level of <10 g/dL, stroke within the previous 10 days, documented hemorrhagic tendencies, or blood dyscrasias)
- •Weight in excess of 325 pounds
- •Resting hypotension (systolic blood pressure of <90mmHg) or resting hypertension (systolic blood pressure of >170mmHg or diastolic blood pressure of >110 mmHg).
- •History of active malignancy requiring concurrent chemotherapy.
- •Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the principal investigator is likely to affect the subject's ability to complete the study.
- •Known allergy to iodinated contrast material
- •Pregnancy or breast feeding
研究组 & 干预措施
rivaroxaban
rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
干预措施: rivaroxaban (Drug)
warfarin
warfarin orally once a day, titrated to INR of 2-3
干预措施: Warfarin (Drug)
结局指标
主要结局
Coronary Artery Calcium (Serial Calcium Scans)
时间窗: 1 year
serial calcium scans
次要结局
- Atherosclerotic Plaque (Measures of Total Atherosclerosis Plaque on Serial CCTA)(1 year)
研究者
Matthew J. Budoff
Principal Investigator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center